Scarica l'app Stockscreener
1.31
0.77%
0.01
Dopo l'orario di chiusura:
1.31
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché IBIO Giù?
Forum
Previsione
Frazionamento azionario
iBio Inc Borsa (IBIO) Ultime notizie
iBio (NASDAQ:IBIO) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Ibio Stock Price Forecast. Should You Buy IBIO? - StockInvest.us
iBio, Inc. SEC Filing (Sep 4, 2026) - Stock Titan
Hundreds of millions of new shares on ballot at iBio (IBIO) - Stock Titan
iBio Inc (IBIO) Valuation: PE, PB & Fair Value Analysis - TradingKey
iBio, Inc. Common Stock (NASDAQ: IBIO) Share Price, IBIO Stock News, IBIO Share Price & Updates - Kalkine
iBio, Inc. (NASDAQ:IBIO) Receives Average Rating of "Buy" from Brokerages - MarketBeat
iBio Q2 EPS Forecast Decreased by Brookline Capital Markets - MarketBeat
iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference - finance.yahoo.com
Insiders Give Up US$33k As iBio Stock Drops To US$1.27 - simplywall.st
iBio Inc. (IBIO) Slides 6.6% to $1.27 as Biotech Stock Approaches Key SupportWyckoff Distribution - dars.gov.et
B. Riley Securities Initiates IBio Inc(IBIO.US) With Buy Rating, Announces Target Price $6 - Moomoo
iBio Advances IBIO-600 Through First Phase 1 Dose Escalation As Cash And Investments Reach $88 Million - Pulse 2.0
iBio, Inc. Revenue Breakdown – NASDAQ:IBIO - tradingview.com
iBio FY2026 Net Loss Widens to $33M on Higher R&D Spending - Minichart
iBio FY 2026: Revenue $100K, Net income ($33.04M), EPS ($0.32) — 10-K Summary - tradingview.com
iBio reports $33 million loss for fiscal 2026, advances pipeline By Investing.com - Investing.com Canada
IBio Reports $33.0 Million Fiscal 2026 Net Loss as Phase 1 Advances - Moomoo
iBio Reports $33.0 Million Fiscal 2026 Net Loss as Phase 1 Advances - Quiver Quantitative
IBIO: Advanced clinical pipeline and secured funding, extending cash runway into fiscal 2028 - tradingview.com
iBio (NASDAQ:IBIO) Releases Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
iBio reports FY2026 net loss of $33.0M, revenue $0.1M and $88.0M cash and investments - tradingview.com
iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update - manilatimes.net
iBio Reports Fiscal 2026 Financial Results and Corporate Update Highlighting Clinical and Pipeline Progress - Quiver Quantitative
IBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update - marketscreener.com
iBio FY26 Results: Net loss widens 80% to $33.0M, R&D up 136% - scanx.trade
iBio (IBIO) Expected to Release Quarterly Earnings on Friday - MarketBeat
iBio (NYSE: IBIO) seeks 500M shares, revises equity plan for warrants - Stock Titan
iBio (IBIO) Chart: Closes 1.72% Lower at $1.43 for the Current Session; Current Setup: the Near-Term Reference Band Stretches From $1.36 to $1.50 in the Available RecordMax Pain Level - vinanet.vn
iBio Inc. (IBIO) Edges Higher Amid Biotech Sector Volatility: Key Levels to WatchAAII Neutral - vinanet.vn
Molly Carr Net Worth (2026) - GuruFocus
iBio (NASDAQ:IBIO) Rating Increased to Hold at Wall Street Zen - MarketBeat
Lynx1 Capital Management (IBIO) corrects 5.4% iBio stake including 2.8M warrant shares - Stock Titan
Vestal Point Capital (IBIO) discloses 4.0M-share iBio position including warrants - Stock Titan
Cormorant Asset Management (IBIO) discloses 9.99% iBio stake via stock and warrants - Stock Titan
Affinity Asset Advisors (IBIO) discloses 5.07M-share, 9.99% stake in iBio - Stock Titan
iBio Inc. (IBIO) Jumps 6.79% to $1.5 as Stock Tests Key Resistance at $1.58Growth Factor - dars.gov.et
IBIO Q2 2026 Earnings: Narrower Loss and 5% Stock Pop Amid Pipeline ProgressGuidance Revision Trend - vinanet.vn
iBio Inc (IBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
iBio, Inc. (NASDAQ:IBIO) Given Average Rating of "Buy" by Analysts - MarketBeat
iBio Inc (IBIO) Stock News Today - TradingKey
NAGE Stock Price and Chart — NASDAQ:NAGE - TradingView
iBio Appoints Molly Carr as Chief Medical Officer - The Globe and Mail
iBio Expands Must-have Cardiometabolic and Obesity Pipeline Investor through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio - Diario AS
IBIO 8-K & SEC Filings - Yahoo Finance
iBio Inc. (IBIO) Edges Higher by 2.82% as Shares Test Key Resistance ZoneATR Trailing Stop - dars.gov.et
iBio (IBIO) awards 430,000 stock options to its Chief Medical Officer - Stock Titan
iBio appoints Molly Carr as chief medical officer By Investing.com - Investing.com India
iBio appoints Molly Carr as chief medical officer - Investing.com
Molly Carr named Chief Medical Officer at iBio - TradingView
iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer - Yahoo Finance
iBio Appoints Endocrinologist Molly Carr as Chief Medical Officer to Advance Obesity and Cardiometabolic Drug Pipeline – Minichart - Minichart
IBIO Q2 2026 Earnings: Narrower-than-Expected Loss Delivers EPS Surprise, Shares Rise 2.21% - vinanet.vn
IBIO|iBio Inc|Price:1.360|Chg%:-0.040 - tradingkey.com
iBio Inc (IBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
iBio Inc (IBIO) Balance Sheet - TradingKey
iBio Inc (IBIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
iBio Inc (IBIO) Cash Flow - TradingKey
iBio Inc (IBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
iBio Inc (IBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
IBIO|iBio Inc|Price:1.385|Chg%:-0.065 - TradingKey
iBio Inc (IBIO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
IBIO Q2 2026 Earnings: Narrower Loss Beats Estimates; Pre-Revenue Status Remains ClearGuidance Accuracy Score - po-news-eg.net
iBio, Inc. Revenue Breakdown – TRADEGATE:0JV0 - TradingView
TradingKey - TradingKey
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):